Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

Einstein, Mark H.; Baron, Mira; Levin, Myron J.; Chatterjee, Archana; Fox, Bradley; Scholar, Sofia; Rosen, Jeffrey B.; Chakhtoura, Nahida; Meric, Dorothée; Dessy, Francis; Datta, Sanjoy; Descamps, Dominique; Dubin, Gary

doi:10.4161/hv.7.12.18281

Cited by 144 publications

(61 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of the primary objective of the head-to-head study was performed at Month 7, where the serum neutralizing antibody (nAb) responses elicited by the HPV-16/18 vaccine were significantly higher than those elicited by the HPV-6/11/16/18 vaccine. 2 The observed differences in the magnitude of immune responses between the vaccines were maintained at Month 24 3 and up to Month 48. 4 This study is now complete and data on vaccine-induced antibody responses up to 5 y postvaccination (Month 60) are presented.…”

Section: Introductionmentioning

confidence: 94%

“…2,3 Briefly, this phase III, observer-blind, randomized, age-stratified, parallel group trial (ClinicalTrials.gov NCT00423046) was initiated in January 2007 and data for the Month 60 analysis were collected up to May 2012 in the USA. Women stratified by age (18-26, 27-35 and 36-45 y) were randomized (1:1 ratio) to receive 0.5 mL of HPV-16/18 vaccine or HPV-6/11/16/18 vaccine according to their recommended 3-dose regimens (Months 0, 1 and 6 or Months 0, 2 and 6, respectively).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

Einstein

Takács

Chatterjee

et al. 2014

Human Vaccines & Immunotherapeutics

Self Cite

107

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 94%

Section: Methodsmentioning

confidence: 99%

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

Einstein

Takács

Chatterjee

et al. 2014

Human Vaccines & Immunotherapeutics

Self Cite

107

View full text Add to dashboard Cite

“…Local reactions: injection site reactions included pain (92.9% bivalent, 71.6% quadrivalent), redness (44.3% bivalent, 25.6% quadrivalent) and swelling (36.5% bivalent, 21.8% quadrivalent) (31). In both vaccines injection site reactions, particularly pain, are usually of short duration and resolve spontaneously (32).…”

Section: Safetymentioning

confidence: 99%

Public health value of universal HPV vaccination

Audisio

Icardi

Isidori

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Highlights► Human Papillomavirus vaccination demands urgent attention. ► The cost-effectiveness of including boys into HPV vaccination programs should be re-assessed. ► Steps must be taken to achieve the target of universal vaccination. ► There is sufficient evidence to urge the EU Community to eradicate all HPV related cancers. ► Policymakers must consider effective vaccination programs in the prevention of cancers. AbstractBackground: The story of Human Papillomavirus vaccination demands reflection not only

show abstract

“…Currently, there are two approved vaccines for the prevention of cervical cancer, Gardasil®, a quadrivalent vaccine directed against HPV-16, HPV-18, HPV-6 and HPV-11 and Cervarix®, a bivalent vaccine directed against HPV-16 and HPV-18 [17,18]. …”

Section: Methodsmentioning

confidence: 99%

Human Papillomavirus Genotype Distribution in Cytologically Screened Women from Northwest Germany

et al. 2013

View full text Add to dashboard Cite

Introduction: In this study, we evaluate the distribution of 24 human papillomavirus (HPV) genotypes in a cohort of 3,381 cytologically screened women from a rural area of northwest Germany, in correlation to cytological diagnoses and histological outcomes. Materials and Methods: We present a retrospective study in which the HPV-genotyping results of women who attended the German cervical screening program were correlated to cytological diagnosis and histological outcome. Results: HPV genotyping showed marked differences among cervical lesions. Although HPV-51 was common in all cervical lesions, it was rarely detected as single-type HPV infection in high-grade cervical intraepithelial neoplasia (CIN)3 (2/118 cases). HPV-16 and 18 were more common in CIN3 (57.6%) than in CIN2 (21.8%), but they were absent in 42.4% of all CIN3 lesions in our cohort. Discussion: Our data show that HPV-16, HPV-31, HPV-51, HPV-53 and HPV-42 are the most prevalent HPV types in the different cervical lesions in this region of northwest Germany.HPV genotyping has been shown to be a powerful tool to triage atypical squamous cells of undetermined significance lesions. Considering the observed heterogeneity of HPV types in CIN2, it could also be useful to triage CIN2+ lesions. Our results underline the usefulness of a morphologically controlled screening program with HPV genotyping as a powerful additional tool.

show abstract

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

Cited by 144 publications

References 45 publications

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

Public health value of universal HPV vaccination

Human Papillomavirus Genotype Distribution in Cytologically Screened Women from Northwest Germany

Contact Info

Product

Resources

About